Home Featured Page 173

Featured

Latest

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Psychedelic Research Bulletin: January 2022

Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

PT290 – Kylea Taylor, M.S., LMFT – Vital Psychedelic Conversations

Religious Practice Under Oregon Measure 109

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Looking Ahead to a Psychedelic 2022

Entheon Biomedical Announces the Approval of DMT Clinical Trial

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of...

Psyched Wellness Announces Additional Positive Results from the 14-day Oral Toxicity...

Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying...

1...172173174...291 Page 173 of 291

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Psychedelic Research Bulletin: January 2022

Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

PT290 – Kylea Taylor, M.S., LMFT – Vital Psychedelic Conversations

Religious Practice Under Oregon Measure 109

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Looking Ahead to a Psychedelic 2022

Entheon Biomedical Announces the Approval of DMT Clinical Trial

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of...

Psyched Wellness Announces Additional Positive Results from the 14-day Oral Toxicity...

Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying...

EDITOR PICKS

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY